Pfizer-BioNTech COVID-19 vaccine

PreclinicalVaccine

PProvidence Therapeutics Holdings Inc.

Pfizer-BioNTech COVID-19 vaccine is one of 51 biologic programs targeting COVID-19. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

TuberculosisActive, not recruiting

COVID-19Preclinical

Active, not recruiting

TuberculosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Activella

Benadryl

1 8

Nadroparin

GSK

Preclinical

1 9

Conventional

PPopulation Health Research Institute

Preclinical

1 10

Opaganib

RRedHill Biopharma Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-194 trials

COVID-19 Vaccine Boosters in Patients With CKD

Terminated·SSunnybrook Health Sciences Centre·Phase 2/3·NCT05022329·273 enrolled

Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers

Completed·RRespiralab··NCT05113472·1,291 enrolled

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04977479·20 enrolled

Show 1 more trial

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

Completed·PProvidence Therapeutics Holdings Inc.·Phase 2·NCT05175742·565 enrolled

Tuberculosis1 trial

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients

Active, not recruiting·UUniversity of Oxford··NCT05571735·133 enrolled

Vaccination1 trial

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04761822·746 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Pfizer-BioNTech COVID-19 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pfizer-BioNTech COVID-19 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pfizer-BioNTech COVID-19 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Providence Therapeutics Holdings Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: PProvidence Therapeutics Holdings Inc.

Pfizer-BioNTech COVID-19 vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-194 trials

Tuberculosis1 trial

Vaccination1 trial

References

Drug Info

Quick Facts

Related News